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Beta-Blockade for
Mitral Regurgitation
Could the Management of
Valvular Heart Disease Actually
Be Moving Into the 21st Century?*
Blase A. Carabello, MD
Houston, Texas
Severe valvular heart disease comprises a group of lesions
that impose a hemodynamic burden on potentially all 4
cardiac chambers. This burden is eventually fatal if left
untreated by timely valve repair or valve replacement.
However, defining the word timely is fraught with uncer-
tainty. Ideally, the procedure should occur early enough to
spare the patient from irreversible left or right ventricular
(and atrial) dysfunction, or both, and certainly from sudden
death, but should be delayed long enough to reduce time-
dependent complications inherent to valve prostheses if
valve repair is impossible to perform. Remarkably, in 2012,
in the midst of a wealth of scientific tools available in other
medical realms, deciding on the “golden moment” for
valvular intervention rests on tools that are at least 50 years
old: the presence of cardiac symptoms, increased heart size,
ejection performance, evidence of pulmonary hypertension,
or a combination thereof (1). To be sure, modern imaging
techniques can give us precise measurements of lesion
severity, of the size and function of the cardiac chambers, of
pulmonary pressure, and of regional and global wall motion.
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In turn, these data form the current basis for timing
mechanical intervention. In modern practice, these markers
have been reasonably satisfactory guides, judging from the
fact that outcomes are good when there is adherence to
guidelines using these parameters (2,3). Unfortunately, by
using symptoms, chamber size, and chamber function to
judge the timing of mechanical intervention, we are looking
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motion by the hemodynamic overload present in all valvular
lesions. Obviously, to come to the point where symptoms or
changes, or both, in cardiac geometry and wall motion have
developed, a series of biological systems must have been
activated or perturbed. This concept potentially presents an
alternative strategy to the timing of mechanical interven-
tion. Instead of waiting for the end result of the pathological
features of valvular heart disease, we could intervene earlier
if we knew that the presence of specific biological events
meant a nearly inevitable progression to the parameters we
now use to judge interventional timing.
The study by Ahmed et al. (4) in this issue of the Journal
gives support for such an approach. It provides yet addi-
tional evidence the adrenergic nervous system becomes
engaged as a support mechanism in mitral regurgitation
(MR) fairly early in the course of disease, before other
thresholds indicating the need for surgery are crossed, and
that beta adrenergic blockade may be beneficial by prevent-
ing the damage done by adrenergic overactivation. It has
been known for a long time that MR begets increased
sympathetic activity (5–8). Catecholamines are increased
both in the experimental animal and in humans with MR.
In the dog, beta-blockade restores depressed contractility
resulting from MR and restores the loss of contractile
elements seen in this model, strongly suggesting a cause-
and-effect relationship between catecholamine excess and
myocardial injury (8). It is also known that contractility
improves in humans after surgery for MR and that this
improvement is associated with a reduction in cat-
echolamines (5,6). In turn, the data from Ahmed et al. (4)
support previous observations that patients with MR receiv-
ing beta blockers have a better outcome than those not
receiving them, regardless of the presence of hypertension or
coronary artery disease (9). In patients randomized to
receive metoprolol, ejection fraction remained unchanged,
whereas it declined in placebo-treated patients. Although
the foibles of ejection fraction in measuring function in MR
are well known, that end-systolic volume tended to increase
without a change in load in the placebo group suggests that
contractility declined in those patients and that this decline
may have been mitigated by beta-blockade. Taken as a
whole, the data suggest a reasonable hypothesis regarding
the pathophysiology of MR. As MR leads to reduced
forward cardiac output, the adrenergic nervous system acts
reflexively to support the circulation. In turn, persistent
sympathetic activity leads to myocardial damage and even-
tual heart failure. We detect the end products of this
scenario when we observe the onset of symptoms and
objective evidence of cardiac dysfunction. These data set the
stage for a large randomized clinical trial to determine
whether beta-blockade would be a useful therapy in tem-
porizing the need for surgery in MR patients.
However, the impact of the current study may go well
beyond the potential for treating MR medically. Suppose
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cardiac and mitral valve function, we also measured cat-
echolamines or perhaps a surrogate such as heart rate
variability, and suppose that we found that after the adren-
ergic nervous system reached a certain level of activity,
eventual cardiac deterioration was almost inevitable. This
may provide a simpler way to time surgery more accurately
and earlier before ventricular structural changes occur. Or, if
not the adrenergic nervous system, other biological changes
in MR must be occurring and could be tracked. For the
heart to enlarge, there must be a change in connective
tissues supporting the myocardium, and these changes
almost surely rely on activation and deactivation of matrix
metalloproteinases, which also could be measured, yield-
ing yet another potential method for timing surgery
(10–12). Alternatively, in the experimental model of MR
in the dog and in papillary muscles of MR patients, there
is an eventual loss of contractile elements (13,14). Thus,
tracking ultrasensitive troponin levels may detect the
early occurrence of these events before overt left ventric-
ular dysfunction develops. In addition, in human MR,
calcium handling is altered, and early detection of these
changes also may give insight into future developments
(15). Or, there may be a host of systemic perturbations
that we have yet to consider.
Since the time of the ancients, man has been fascinated
with the movement of the heart, and in the 21st century, we
have developed incredibly sophisticated machines to detect
and measure this movement. Impairment of this motion
together with changes in cardiac geometry are the manifes-
tations of advanced pathological processes that already have
injured the myocardium and have impaired its function.
The current study by Ahmed et al. (4) suggests that
biological perturbation occurs well before changes in ejec-
tion performance. If we can measure such changes simply
and inexpensively, we may to able to advance the under-
standing and management of valvular heart disease from
watching the heart move to detecting the processes that
impair function while using those tools to time better or
even delay the need for mechanical intervention.
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